GRAIL, Inc. (GRAL)
139.92
+2.55
(+1.86%)
USD |
NASDAQ |
Oct 13, 14:02
GRAIL EPS Diluted (Quarterly) : -2.557 for June 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -2.557 |
| March 31, 2026 | -2.293 |
| December 31, 2025 | -2.435 |
| September 30, 2025 | -2.463 |
| June 30, 2025 | -3.185 |
| March 31, 2025 | -3.096 |
| December 31, 2024 | -2.864 |
| September 30, 2024 | -3.785 |
| Date | Value |
|---|---|
| June 30, 2024 | -51.06 |
| March 31, 2024 | -7.050 |
| December 31, 2023 | -6.039 |
| September 30, 2023 | -28.71 |
| June 30, 2023 | -6.217 |
| March 31, 2023 | -6.237 |
| September 30, 2020 | -0.58 |
| September 30, 2019 | -0.49 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Moderna, Inc. | -1.965 |
| Twist Bioscience Corp. | -0.5617 |
| Prime Medicine, Inc. | -0.2376 |
| Kailera Therapeutics, Inc. | -0.8587 |
| Arrowhead Pharmaceuticals, Inc. | -1.355 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -110.25M |
| Revenue (Quarterly) | 44.69M |
| Total Expenses (Quarterly) | 154.93M |
| Enterprise Value | 5.365B |
| Gross Profit Margin (Quarterly) | -30.61% |
| Profit Margin (Quarterly) | -246.7% |
| Earnings Yield | -6.97% |
| Normalized Earnings Yield | -6.672 |